Special Issue "Hepatocellular Carcinoma: Epidemiology, Pathogenesis and Treatment"

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: 15 June 2023 | Viewed by 850

Special Issue Editors

Dr. Francesco Tovoli
E-Mail Website
Guest Editor
Dipartimento di Scienze Mediche e Chirurgiche, Alma Mater Studiorum Università di Bologna, Bologna, Italy
Interests: hepatocellular carcinoma; outcome; diagnosis; immunotherapy; artificial intelligence; lenvatinib; trans-arterial chemoemboilzation; selective internal radiotherapy; microwave ablation; surgery
Special Issues, Collections and Topics in MDPI journals
Dr. Luca Ielasi
E-Mail Website
Guest Editor
Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy
Interests: hepatocellular carcinoma; cholangiocellular carcinoma

Special Issue Information

Dear Colleagues, 

The topic of liver cancer is receiving increasing attention. Hepatocellular carcinomas are still the primary liver cancers, with the highest prevalence and death toll worldwide. Intrahepatic cholangiocarcinoma is also on the rise, and an ever-increasing number of rare liver cancers are being reported. Epidemiology, pathogenesis, and response to surgical, locoregional, and systemic treatments are all elements of particular interest which need further elucidation by future studies. This Special Issue will cover all aspects, and welcomes both original research and comprehensive review papers to guide a wide readership toward the most recent and ground-breaking research in this complex field.

Dr. Francesco Tovoli
Dr. Luca Ielasi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatocellular carcinoma
  • liver cancer
  • epidemiology
  • pathogenesis
  • treatment

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Review
Potential Molecular Targeted Therapy for Unresectable Hepatocellular Carcinoma
Curr. Oncol. 2023, 30(2), 1363-1380; https://doi.org/10.3390/curroncol30020105 - 18 Jan 2023
Viewed by 707
Abstract
Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal cancers, representing a serious worldwide health concern. The recurrence incidence of hepatocellular carcinoma (HCC) following surgery or ablation is as high as 70%. Thus, the clinical applicability of standard surgery and other [...] Read more.
Hepatocellular carcinoma (HCC) is one of the most prevalent and lethal cancers, representing a serious worldwide health concern. The recurrence incidence of hepatocellular carcinoma (HCC) following surgery or ablation is as high as 70%. Thus, the clinical applicability of standard surgery and other locoregional therapy to improve the outcomes of advanced HCC is restricted and far from ideal. The registered trials did not identify a treatment that prolonged recurrence-free survival, the primary outcome of the majority of research. Several investigator-initiated trials have demonstrated that various treatments extend patients’ recurrence-free or overall survival after curative therapies. In the past decade, targeted therapy has made significant strides in the treatment of advanced HCC. These targeted medicines produce antitumour effects via specific signals, such as anti-angiogenesis or advancement of the cell cycle. As a typical systemic treatment option, it significantly improves the prognosis of this fatal disease. In addition, the combination of targeted therapy with an immune checkpoint inhibitor is redefining the paradigm of advanced HCC treatment. In this review, we focused on the role of approved targeted medicines and potential therapeutic targets in unresectable HCC. Full article
(This article belongs to the Special Issue Hepatocellular Carcinoma: Epidemiology, Pathogenesis and Treatment)
Show Figures

Figure 1

Back to TopTop